Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
October 09 2015 - 9:25AM
Marketwired
Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech
Now Securing Europe for Pancreatic Cancer Treatment BONITA,
CA-(Marketwired - October 09, 2015) - The combination of
PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell
encapsulation technology, Cell-in-a-Box® with low doses of
ifosfamide has already won the FDA's "Orphan Drug" status here in
the U.S., and now it seems the company will also be awarded the
“Orphan Designation” with the European Medicines Agency (EMA),
which would guarantee 10 years of competition-free marketing when
the pancreatic cancer treatment is approved. In the world of
biopharma, it doesn't take long for a company to copy or mimic a
popular, successful drug. In fact, for some less-common diseases,
the industry realizes that merely sharing the revenue generated by
a small niche may not even be worth the effort, meaning those rare
or difficult-to-treat diseases often go completely unaddressed. If
all goes as planned for PharmaCyte and its novel pancreatic cancer
treatment, not only does it stand to introduce a game-changing
therapy to the market, it could be rewarded for its efforts with
years of exclusive marketing rights in for its patented treatment.
In the U.S., the FDA has given PharmaCyte the Orphan Designation,
which will give the company 7 years of marketing exclusivity when
the company’s pancreatic cancer treatment is approved. Now, the
company has hinted that it is close to securing the Orphan
Designation with the EMA in Europe, which will offer PharmaCyte 10
years of marketing exclusivity when its treatment is approved.
PharmaCyte Biotech is the developer of a live-cell encapsulation
platform biotechnology known as Cell-in-a-Box®. In simplest terms,
Cell-in-a-Box is a means of encapsulating and implanting living
cells into a patient's body where they can drive a specific
therapeutic effect. In the case of PharmaCyte's pancreatic cancer
therapy, these encapsulations (about the size of the head of a pin)
contain cells that produce an enzyme, which activates a
cancer-killing drug called ifosfamide. The advantage of this method
of drug-activation is pinpoint placement within the body.
Ifosfamide is usually converted to its cancer-killing form in the
liver. It works, but the bulk of the drug gets "lost" before
reaching the pancreatic tumor given the pancreas is the last organ
on the circulatory system. By moving the “activation site” from the
liver to the site of the tumor - by implanting about 300 of these
pinhead-sized encapsulations at the site of the tumor - ifosfamide
isn't converted into its useful form until the last possible
moment, insuring maximum impact of the drug at a minimal dosage.
And, the company has already seen compelling results with this
approach through the first part of its phase 1/2 trials. In a test
comparing the benefit of the Cell-in-a-Box delivery of ifosfamide
versus historical results for the drug gemcitabine alone, the
PharmaCyte approach improved the median survival time from 28 to 44
weeks. Equally impressive is the fact that the number of one-year
survivors of the study's patients increased from 18% to 36%. That
was enough to get the FDA's attention, which has since granted the
combination of Cell-in-a-Box and ifosfamide an "Orphan Drug"
designation. Better yet, per Wednesday's news release, the company
is in the process of securing the same Orphan Designation with the
European Medicines Agency according to PharmaCyte CEO Kenneth L.
Waggoner. The FDA and other sovereign agencies created the Orphan
Drug Designation as a means to encourage the development of
treatments for rare diseases that may not otherwise be addressed by
the industry. One of the more advantageous benefits of the Orphan
Drug status is generous tax breaks, though the biggest upside may
be multi-year marketing exclusivity. The FDA's
marketing-exclusivity rights for its designated Orphan Drugs extend
for 7 years after the drug is approved. The EMA's orphan drug
program is similar, though it guarantees marketing exclusivity for
a period of 10 years. That's practically an eternity for a drug,
during which time - if ifosfamide and Cell-in-a-Box are approved -
PharmaCyte Biotech would continue to develop its biotechnology as a
means of treating diabetes, and even brain cancer. At stake is a
piece of an underserved $2 billion pancreatic cancer market, a
market that could prove very lucrative with the therapy's exclusive
marketing rights being in place for several years after any
approval. The next step is the upcoming phase 2b clinical trial
using Cell-in-a-Box® with low doses of the drug ifosfamide in
hopes of providing patients with a treatment that meets a current
unmet medical need in the treatment of advanced pancreatic cancer.
Read more articles and our research report on PharmaCyte Biotech
atwww.smallcapnetwork.com. About SmallCap Network The SmallCap
Network is an electronic publication committed to providing our
readers with useful information on publicly traded companies.
SmallCap Network sometimes contracts with third parties or publicly
traded companies and receives compensation from them in the form of
cash and sometimes restricted securities as payment for publishing
information and opinion about the company and the trading market
for their securities. Principals of the SmallCap Network may also
purchase or sell securities of the companies in the open market
from time to time. The positions that the SmallCap Network or its
principals maintain in securities of the companies are disclosed
here and should be considered in making an investment decision
regarding companies mentioned on the SmallCap Network site. The
SmallCap Network may be deemed to have a conflict of interest
between its open market activity and positions in these securities
and the timing of and opinions expressed in its publications
concerning these companies. SmallCap Network has been compensated
$10,000 and has been pledged a fee of $4,000 per month by a third
party for market awareness and other advertising services on PMCB.
All statements and opinions expressed herein are those of the
editors and staff of SmallCap Network and are subject to change
without notice. The SmallCap Network maintains editorial control
over its publications and the companies profiled therein do not
have any editorial rights concerning the information published
about them. No information contained in our website, e-mail
communications or our publications should be considered as a
solicitation to purchase or sell any of the securities mentioned.
SmallCap Network, its principals or employees are not registered
investment advisors or a registered securities broker dealer. We do
not undertake or represent to make investment recommendations or to
give advice pertaining to the purchase or sale of the securities
mentioned in our web site, e-mail communications or publications.
While we believe all sources of information provided by us and
contained in our publication to be accurate and reliable, we cannot
and do not guarantee the accuracy of information we received from
third parties. Furthermore, SmallCap Network has not independently
verified such information provided within our publication. Readers
are encouraged to do their own due diligence before investing in
any securities mentioned in this article. Investing in securities
is speculative and carries a high degree of risk. We encourage our
readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange
Commission ("SEC") at http://www.sec.gov and/or the
National Association of Securities Dealers ("NASD")
at http://www.finra.org. We also recommend that you read the
SEC advisory to investors concerning Internet Stock Fraud, which
can be found athttp://www.sec.gov/consumer/cyberfr.htm. Readers can
review all public filings by companies at the SEC's EDGAR page. The
NASD has published information on how to invest carefully at its
web site. The information found in this Newsletter is protected by
the copyright laws of the United States and may not be copied, or
reproduced in any way without the expressed, written consent of The
SmallCap Network. CONTACT INFORMATION Contact: SmallCap Network
customerservice@smallcapnetwork.com